Reaction

Monoparesis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,797 reports · 54 co-occurring drugs

As of the last recalculation, Monoparesis appears in 1,797 FAERS reports alongside 54 co-occurring drug terms. The strongest observed disproportionality signal is DOXEPIN HYDROCHLORIDE (PRR 82.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Doxepin Hydrochloride	86	82.8	83.4
Siponimod	37	49.0	49.2
Rabeprazole	86	47.2	47.3
Pramipexole	58	45.3	45.4
Rosuvastatin Calcium	80	34.4	34.5
Rabeprazole Sodium	72	31.8	31.9
Captopril	17	20.7	20.7
Thiamine Hydrochloride	19	17.9	17.9
Baclofen	112	16.0	16.0
Dalfampridine	84	14.2	14.2
Thiamine Hydrochloride, Riboflavin 5 Phosphate Sodium, Dexpanthenol And Niacinamide	36	14.0	14.0
Nebivolol	19	14.0	14.0
Felodipine Extended-Release Tablets	13	13.3	13.3
Felodipine	13	13.3	13.3
Bisoprolol Fumarate	143	13.2	13.2
Cyanocobalamin	33	11.8	11.8
Bupivacaine	9	11.2	11.2
Biotin	29	10.9	10.9
Temazepam	33	10.3	10.3
Fingolimod Hcl	72	10.0	10.0
Basiliximab	10	9.9	9.9
Dimethyl Fumarate	96	9.5	9.5
Vemurafenib	9	8.7	8.7
Brentuximab Vedotin	7	7.9	7.9
Amlodipine Besylate And Valsartan	7	7.3	7.4
Nebivolol Hydrochloride	21	7.3	7.3
Fondaparinux Sodium	5	7.2	7.2
Axicabtagene Ciloleucel	6	7.1	7.1
Ritonavir 100 Mg	9	7.0	7.0
Interferon Beta-1A	110	7.0	7.0
Interferon Beta-1B	11	6.7	6.7
Brivaracetam	5	6.5	6.5
Ocrelizumab	33	6.3	6.3
Alteplase	8	6.2	6.2
Cytarabine	31	6.1	6.1
Cladribine	5	6.0	6.0
Bleomycin Sulfate	5	5.6	5.6
Doxorubicin	37	4.9	4.9
Polatuzumab Vedotin	4	4.8	4.8
Dabigatran Etexilate Mesylate	29	4.7	4.7
Ofatumumab	13	4.6	4.6
Irinotecan Hydrochloride	5	4.5	4.5
Blinatumomab	4	4.4	4.4
Teriflunomide	17	4.4	4.4
Dabigatran Etexilate	29	4.4	4.4
Oxaliplatin	27	4.3	4.3
Alpelisib	3	4.0	4.0
Drospirenone And Ethinyl Estradiol	15	4.0	4.0
Botulinum Toxin Type A	4	3.7	3.7
Eltrombopag Olamine	7	3.5	3.5
Fam-Trastuzumab Deruxtecan-Nxki	3	3.5	3.5
Durvalumab	6	3.4	3.4
Glatiramer Acetate	16	3.1	3.1
Pimavanserin Tartrate	7	1.5	1.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.